Dr. Lal Path Labs Ltd.

15%

s Leading & Trusted Diagnostics Company 70+ years of experience in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 L

13%

ostics Company 70+ years of experience in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 Largest* diagnostics chain

120%

nce in the field of diagnostics 15% 3 Year Revenue CAGR 13% 3-Year Normalised EBITDA CAGR 120% Equity Dividend for FY 22-23 Largest* diagnostics chain in the country with PAN India presenc

rs 24

growth 36 NABL accredited Labs; 2 CAP accredited Labs 111 Mn patients serviced in last 5 years 24% ROCE Excl. Cash & Investments 5,191 Pathology & Radiology tests; Comprehensive Test menu 2

Rs. 877

Test menu 277 Labs; Geographically spread-out network 5,102 Patient Service Centers (PSC’s) Rs. 877 Cr. Cash & Investments as on 30th June, 2023 Rs. 146 Cr. OD/TL as on 30th June, 2023 As on Mar

Rs. 146

k 5,102 Patient Service Centers (PSC’s) Rs. 877 Cr. Cash & Investments as on 30th June, 2023 Rs. 146 Cr. OD/TL as on 30th June, 2023 As on March 31, 2023 *Largest on the basis of revenue and presenc

INR 528

1008 PUP’s of Suburban Diagnostics As on March 31, 2023 5 Q1 FY24 – Key Performance Highlights INR 528 Cr Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenu

9.7%

ics As on March 31, 2023 5 Q1 FY24 – Key Performance Highlights INR 528 Cr Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenue +7.6% INR 84 Cr PAT 15

INR 154

s on March 31, 2023 5 Q1 FY24 – Key Performance Highlights INR 528 Cr Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenue +7.6% INR 84 Cr PAT 15.4% Margin

28.4%

– Key Performance Highlights INR 528 Cr Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenue +7.6% INR 84 Cr PAT 15.4% Margin INR 112 Cr Swasthfit Reven

INR 541

nce Highlights INR 528 Cr Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenue +7.6% INR 84 Cr PAT 15.4% Margin INR 112 Cr Swasthfit Revenue 22% Contr.

7.6%

Non-Covid Revenue +9.7% INR 154 Cr Normalised EBITDA* 28.4% Margin INR 541 Cr Total Revenue +7.6% INR 84 Cr PAT 15.4% Margin INR 112 Cr Swasthfit Revenue 22% Contr. * Normalised EBITDA excl

“This encouraging shift is expected to gain traction in the coming period, helping large national players like us to further cement our leadership position in the country.” “Over the next few years, we expect a rapid shift of market share from unorganized to organized, driven by changing industry dynamics and certain intrinsic benefits available to large organised players.”

“These efforts aim to elevate the patient experience and provide tailored solutions to meet customized needs.”

Managing Director said

1

Managing Director said

Commenting Uppiliappan, Chief Executive Officer said: performance, Mr. the on Bharath “As a frontrunner in organized diagnostics, we believe we have consistently met patient expectations on service parameters. We are focused single mindedly on driving volume growth and our methodical approach to network expansion will take lead. Given our strong operating model and brand affinity in both B2C and B2B segments, I see the Company gain share from the un- organized space. There is synergy to be leveraged across both our brands and this will form the basis for business performance in the Western India as we fully tap the potential of our new RRL at Vidyavihar. We are constantly focused on expanding our presence to reach a larger number of customers, especially in the tier 3 and 4 cities. Diagnostics industry in India remains dynamic, offering ample opportunities for future expansion. The industry is shifting gears from being an unorganized market largely to one that is organized. This encour